LONDON, March 9, 2016 /PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE: SN), the global medical technology business, today announced the launch of the TRUCLEAR 5C Hysteroscope Set for the combined diagnosis and removal of abnormalities within the uterine cavity. The ability to identify and remove intrauterine pathologies using a single scope is known as "see-and-treat" by surgeons and reduces the need for patients to schedule multiple visits.
The 5C Hysteroscope builds on the success of the innovative TRUCLEAR 5.0 System, which studies suggest may represent the best choice for office hysteroscopy.i A recent scientific review of published data related to 1,184 patients demonstrated that the TRUCLEAR 5.0 System outperformed conventional resectoscopy and conventional outpatient operative hysteroscopy on such issues as safety, efficacy, surgical complications, estimated learning curve and operating time. i
According to gynecologist feedback gathered after using the 5C device, the new 5C Hysteroscope's slanted tip allowed for easier insertion into the cervix, thus minimizing the need for dilation and potentially improving the overall patient experience.ii
"The TRUCLEAR 5C Hysteroscope Set allows me to perform both diagnostic and operative hysteroscopy in a way that is more efficient for both me and my patients," says Dr. Daniel B. Williams of Houston Fertility Institute. "If polyps or fibroids are identified, I am then able to use the TRUCLEAR System for pathology removal without changing scopes."
"We are excited by the opportunity the TRUCLEAR 5C offers surgeons to diagnose and treat uterine abnormalities in the most efficient and patient-friendly way possible," said Mira Sahney, General Manager for ENT and Gynecology at Smith & Nephew. "And as clinical evidence continues to support the use of office-based hysteroscopic procedures, we will continue to pioneer advancements that help save healthcare resources and avoid unnecessary hospital admissions."
About TRUCLEAR Procedure
During the procedure, a scope (known as a hysteroscope) is inserted through the cervix allowing the gynecologist to see inside the uterus. Through that same scope, the doctor then inserts small instruments that mechanically cut and remove tissue, such as polyps and fibroids, from the uterus. Unlike some other treatment options, the mechanical design of the TRUCLEAR Procedure means there is no risk of electrical injury to the lining of the uterus.
For detailed product information, including indications for use, contraindications, effects, precautions and warnings, please consult the product's Instructions for Use (IFU) prior to use at www.sntruclear.com.
About Smith & Nephew
Smith & Nephew is a global medical technology business dedicated to helping healthcare professionals improve people's lives. With leadership positions in Orthopaedic Reconstruction, Advanced Wound Management, Sports Medicine and Trauma & Extremities, Smith & Nephew has around 15,000 employees and a presence in more than 100 countries. Annual sales in 2015 were more than $4.6 billion. Smith & Nephew is a member of the FTSE100 (LSE:SN, NYSE: SNN).
This document may contain forward-looking statements that may or may not prove accurate. For example, statements regarding expected revenue growth and trading margins, market trends and our product pipeline are forward-looking statements. Phrases such as "aim", "plan", "intend", "anticipate", "well-placed", "believe", "estimate", "expect", "target", "consider" and similar expressions are generally intended to identify forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that could cause actual results to differ materially from what is expressed or implied by the statements. For Smith & Nephew, these factors include: economic and financial conditions in the markets we serve, especially those affecting health care providers, payers and customers; price levels for established and innovative medical devices; developments in medical technology; regulatory approvals, reimbursement decisions or other government actions; product defects or recalls or other problems with quality management systems or failure to comply with related regulations; litigation relating to patent or other claims; legal compliance risks and related investigative, remedial or enforcement actions; disruption to our supply chain or operations or those of our suppliers; competition for qualified personnel; strategic actions, including acquisitions and dispositions, our success in performing due diligence, valuing and integrating acquired businesses; disruption that may result from transactions or other changes we make in our business plans or organisation to adapt to market developments; and numerous other matters that affect us or our markets, including those of a political, economic, business, competitive or reputational nature. Please refer to the documents that Smith & Nephew has filed with the U.S. Securities and Exchange Commission under the U.S. Securities Exchange Act of 1934, as amended, including Smith & Nephew's most recent annual report on Form 20-F, for a discussion of certain of these factors. Any forward-looking statement is based on information available to Smith & Nephew as of the date of the statement. All written or oral forward-looking statements attributable to Smith & Nephew are qualified by this caution. Smith & Nephew does not undertake any obligation to update or revise any forward-looking statement to reflect any change in circumstances or in Smith & Nephew's expectations.
™ Trademark of Smith & Nephew. Certain marks registered US Patent and Trademark Office.
i Noventa, M. MD, Ancona, E., MD, Quaranta, M., MD, Vitagliano, A., MD, Cosmi, E., MD, D'Antona, D., MD, and Gizzo, S., MD. (2015)
"The Icon of Hysteroscopic Future or Merely a Marketing Image? A Systematic Review Regarding Safety, Efficacy, Advantages and Contraindications". Reproductive Sciences, Published Online.
ii Data on file
SOURCE Smith & Nephew